多靶点蛋白酪氨酸激酶抑制剂类抗肿瘤药物的研究进展

clooxygenase(COX)inhibition1J21J1Ethnopharmacol1,2011,133(2):928-93011372TakaoKonoshima,MidoriTakasaki,HarukuniTokuda,etal1Cancerchemopreventiveactivityofaniridoidglycoside,8-acetylharpagide,fromAjugadecumbens1J21CancerLetters,2000,157(1):87-9211382JaouadElHilaly,Badi½aLyoussi1HypoglycaemiceffectofthelyophilisedaqueousextractofAjugaivainnormalandstreptozotocindiabeticrats1J21J1Ethnopharmacol1,2002,80(2-3):109-11311392JaouadE-lHilaly,AdilTahraoui,ZafarH1Israili,etal1Hypolipidemiceffectsofacuteandsub-chronicadministrationofanaqueousextractofAjugaivaL1wholeplantinnormalanddiabeticrats1J21J1Ethnopharmacol1,2006,105(3):441-44811402KacemRharrabe,FouadSayah,Ren†LaFont1DietaryEffectsofFourPhytoecdysteroidsonGrowthandDevelopmentoftheIndianMealMoth,Plodiainterpunctella1J21JournalofInsectScience,2010,10(13):1-1211412,,,11J21,2009,18(11):1849-185511422M1IqbalChoudhary,SarfrazAhmadNawaz,Zaheer-u-lHaq,etal1Withanolides,anewclassofnaturalcholinesteraseinhibitorswithca-lciumantagonisticproperties1J21Biochem1Biophys1Res1Commun1,2005,334(1):276-28711432,11J21,2002,14(5):40-4111442JaouadElHilaly,ZafarH1Israili,Badi½aLyoussi,etal1AcuteandchronictoxicologicalstudiesofAjugaivainexperimentalanimals1J21J1Ethnopharmacol1,2004,91(1):43-501张秋荣,陈婷,于康,王慧,周广强,朱楠,冯贝贝,刘宏民(450001):多靶点的蛋白酪氨酸激酶抑制剂药物的研究成为近几年来抗肿瘤药物研究的热点,本文整合国内外相关文献资料,简要介绍了该类药物的抗肿瘤作用机理,综合阐述了酪氨酸激酶抑制剂的研究进展:多靶点;酪氨酸激酶;抑制剂;抗肿瘤药物:R73011:A:1006-3765(2012)-02-0007-04:,(196518-):0371-67781896,E-mail:zhqr010@yahoo1com1cn:,,:E-mail:liuhm@zzu1edu1cn81172937Advancesinthestudyontheantineoplasticagents--mult-itargettyrosinekinaseinhibitorsZHANGQiu-rong,CHENTing,YUkang,WANGHui,ZHOUGuang-qiang,ZHUNan,FENGBe-ibei,LIUHong-min(NewDrugResearchandDevelopmentCenter,ZhengzhouUniversity,Zhengzhou450001)ABSTRACT:Inrecentyearstheresearchofmult-itargettyrosinekinaseinhibitorshadbecomeahotspotonant-ineoplasticagents,summarizingthedomesticandforeignliterature,thepresentreviewgaveabriefintroductionoftheantitumormechanismofthose,anddiscussedcurrentapproachesthatmult-itargettyrosinekinaseinhibitorsincancertreatmentandresearch1KEYWORDS:Mult-itarget;Tyrosinekinases;Inhibitors;Antineoplasticagents,,,,,,112,(RTKs)(nrPTKs)122,RTKs:¹(EGFR),(NSCLC);º#7#StraitPharmaceuticalJournalVol24No122012(PDGFR),,;»(VEGF),;¼(FGFR),,,;½,RTKs(HGFR)(NGFR)TrkTienrPTKsSrcJakFAKAckFesRakBrk,ATP,;,,,,,,,,,1111(imatinibmesylate,Gleevec),,2001510(FDA),(CML)132200221FDA:142;(SCLC)1521622-,4-1(4--1-)2-N-14--3-114-(3-)-2-222,bcr-ablC-kit(PDGFR),ATP,,bcr-abl,172112(sorafenib,Nexavar),ONYX,200512FDA,200710;,,Ó;Ò182,192,4-{4-13-(4--3--)-2-}--2-,RAF/MEK/ERK,,1102113(Sunitinib,Sutent),,20061(FDA)1112,Ó,Ò,112,132N-12-()2-5-1(Z)-(5--1,2--2--3H--3-)2-2,4--1H--3-,1142114(lapatinib,Tykerb)EGFR/ErbB-220073FDA,Her-2,tras-tuzumabHER-21152HER-2,,HER-2ÓÒ4-,N-(3-4-{1(3-)2})-6-15-({12-()2})-2-24-(4-),EGFR(ErbB-1)/HERE(ErbB-2)ATP,,EGFR(ErbB-1)/HERE(ErbB-2),,1162115(nilotinib,Tasigna)20071029FDA#8#2012242(CML),1172,4--N-13-(4--1H--1-)-5-()2-3-14-(3-)-2-2Bcr-Abl,Kit(PDGFR)116(dasatinib,Sprycel)20066FDA,,,,1182:N-(2--6-)-2-116-14-(2-)-1-2-2--4-22-5-ABLSRC,IMABLATPIMA,ABLATP119,2022211(vatalanib,PTK787)2006VEGFRPDGFR,(AMD)1212,N-(4-)-4-(-4-)--1-ATP(VEG-FR)VEGFR-1/Fit-1VEGFR-2/KDRVEGFR-3/FLT-4B(PDGFRB)c-Kit,,,,:,,;,-212(Vandertanib,Zactima)20051120061(COMP)(NSCLC),Ó24:122,232,NSCLC124,252,:N-(4--2-)-6--7-1(1--4)2-4-EGFRVEGFRRET,,,G112623,;,;,,112LisGerald1Inhibitionoftumorangiogenesisbysyntheticreceptorty-rosinekinaseinhibitors1J21DrugsDiscoveryToday,2000,5(8):344-3531122Sebolt,LeopoldJS,EnglishJM1Mechanismsofdruginhibitionofsig-nalingmolecules1J21Nature,2006,441:457-46211321STI5711J21,2003,38(1):69-711142ToufengJ,Haiimen,TakahiroT1STI571(Glivec)suppressestheex-pressionofvascularendothelialgrowthfactorinthegastrointestinalstromaltumorcellline,IST-T11J21worldJournalofGastroen-terology,2006,4(5):703-7081152,1-1J21,2003,24(8):503-5061162,1RAINOVNG1STI571(GBM)1J21,2004,31(15):856-8591172SavageDG,AntmanKH1Imatinibmasylate-aneworaltargetedthera-py1J21NEnglJMed,2002,346(9):683118211J21,2009,9(1):76-801192,11J21,2007,46(11):955-95711102WilhelmSM,CarterC,TanqL1BAY43-9006exhibitsbroadspec-trumoralantitumoractivityandtargetstheRAF/MEK/ERKpath-wayandreceptortyrosinekinasesvinolvedintumorprogressionandangiogenesis1J21CancerRes,2004,64(19):7099-710911112RockEP,GoodmanV,JiangJX,etalFoodandDrugAdministrationdrugapprovalsummary:Sunitinibmalateforthetreatmentofgas-trointestinalstromaltumorandadvancedrenalcellcarcinoma1J21Oncologist,2007,12(1):107-11311122PatyaS,LaiedAD,MendelDB,etalSU14813:anovelmultiplere-ceptortyrosinekinaseinhibitorwithpotentantiangiogenicandant-itumoractivity1J21MolCancerTher,2006,5(7):1774-178211132IzzedNE,BuhaEsculI,RixeO,etal1Sunitinibmalate1J21CancerChemotherPharmacol,2007,60(3):357-36411142FaivreS,DelbadoC,VeraK,etal,Safety,pharmacokinetic,andant-itumoractivityofSU11248,anoveloralmultitargettyrosinekinaseinhibitor,inpatientswithcancer1J21JClinOncol,2006,24(1):25-351#9#StraitPharmaceuticalJournalVol24No1220121152JohnstonS,TrudeauM,KaufmanB,etal1PhaseÒstudyo